New Perspectives on mTOR Inhibitors (Rapamycin, Rapalogs and TORKinibs) in Transplantation

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.12893
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Rapalogs and mTOR Inhibitors as Anti-Aging Therapeutics

Journal of Clinical Investigation
Medicine
2013English

New Perspectives on the Use of mTOR Inhibitors in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-Versus-Host Disease

British Journal of Clinical Pharmacology
Pharmacology
2016English

Transplantation: Are Calcineurin Inhibitors Safer Than mTOR Inhibitors?

Nature Reviews Nephrology
Nephrology
2012English

Conversion From Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplantation: A Single Centre Experience

Turkish Nephrology, Dialysis and Transplantation Journal
SurgeryUrology
2014English

GOLPH3 Modulates mTOR Signalling and Rapamycin Sensitivity in Cancer

Nature
Multidisciplinary
2009English

New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research
Cancer ResearchOncology
2004English

Impact on Autophagy and Ultraviolet B Induced Responses of Treatment With the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and Pp242 in Human Keratinocytes

Oxidative Medicine and Cellular Longevity
BiochemistryMedicineCell BiologyAging
2017English

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Letter: Mechanistic Target of Rapamycin Inhibitors-Do They Impact on Recurrence of Hepatocellular Carcinoma After Liver Transplantation?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy